论文部分内容阅读
目的:评价晚期胰腺癌患者接受吉西他滨联合奥沙利铂方案合并高强度聚焦超声治疗的临床疗效。方法:抽取90例晚期胰腺癌患者的临床资料展开回顾性分析:57例接受吉西他滨联合奥沙利铂合并高强度聚焦超声治疗,归为观察组;33例仅接受吉西他滨与奥沙利铂的联合治疗,归为参照组。比较两组患者的病情治疗情况及不良反应情况,对本组合并治疗方案做出评价。结果:两组患者的不良反应发生率并未出现明显差异(P>0.05);观察组治疗有效率为42.11%(24/57),对照组治疗有效率为24.24%(8/33),组间差异比较存在明显的统计学差异(P<0.05)。结论:为胰腺癌晚期患者采取吉西他滨联合奥沙利铂合并高强度聚焦超声治疗效果安全,近期疗效较好,具备广泛应用于临床的价值。
Objective: To evaluate the clinical efficacy of gemcitabine plus oxaliplatin combined with high intensity focused ultrasound in patients with advanced pancreatic cancer. Methods: The clinical data of 90 patients with advanced pancreatic cancer were retrospectively analyzed. Fifty-seven patients were treated with gemcitabine combined with oxaliplatin and high-intensity focused ultrasound and were assigned to the observation group. 33 patients received only gemcitabine combined with oxaliplatin Treatment, classified as reference group. The two groups of patients were compared the condition of treatment and adverse reactions, to make the evaluation of the combined treatment of this group. Results: There was no significant difference in adverse reactions between the two groups (P> 0.05). The effective rate of the observation group was 42.11% (24/57), that of the control group was 24.24% (8/33) There was significant difference between the two groups (P <0.05). Conclusion: The effect of gemcitabine combined with oxaliplatin combined with high intensity focused ultrasound is safe for the patients with advanced pancreatic cancer. The curative effect is good in the near future and has the value of being widely used in clinic.